Parkinsonism is a chronic progressive motor disorder. Treatment strategy is to increase central nervous system (CNS) dopamine and decrease acetylcholine. Antiparkinsonian drugs are classified into drugs that enhance dopamine activity, dopamine metabolism inhibitors, and drugs depressing cholinergic activity. Dopamine has no therapeutic value since it does not cross blood-brain barrier (BBB). Levodopa is a prodrug, which is able to cross the BBB. Carbidopa and benserazide are peripheral dopa decarboxylase inhibitors. Dopamine releasers, dopamine receptor agonists, dopamine metabolism inhibitors, central anticholinergics, drug-induced parkinsonism, and drugs for Alzheimer’s disease are the other discussed topics of this chapter.